enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q2 2024 vs. Q1 2024
How the institutions holding enGene Therapeutics Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 31 | 30 | −1 |
| Shares | 31.7M | 32.6M | +951.1K (+3.0%) |
| Value | $536.1M | $307.1M | −$228.9M (−42.7%) |
New holders (6)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sr One Capital Management, LP | 500,000 | $4.71M | 1.48% |
| Silverarc Capital Management, LLC | 263,841 | $2.49M | 0.61% |
| Ameriprise Financial Inc | 12,524 | $118.1K | 0.00% |
| UBS Group AG | 3,370 | $31.8K | 0.00% |
| Wells Fargo & Company | 972 | $9.17K | 0.00% |
| ADAR1 Capital Management, LLC | 600 | $5.66K | 0.00% |
Sold out (7)
Institutions that held enGene Therapeutics Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Commodore Capital LP | 1,250,000 | $21.2M |
| Deerfield Management Company, L.P. (Series C) | 800,000 | $13.6M |
| Altitude Crest Partners Inc. | 120,289 | $2.04M |
| Polar Asset Management Partners Inc. | 65,225 | $1.10M |
| Cubist Systematic Strategies, LLC | 9,757 | $165.4K |
| JPMorgan Chase & Co | 289 | $4.90K |
| Qube Research & Technologies Ltd | 14 | $237 |